✦ LIBER ✦

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

✍ Scribed by Novello, S; Scagliotti, G V; Rosell, R; Socinski, M A; Brahmer, J; Atkins, J; Pallares, C; Burgess, R; Tye, L; Selaru, P

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ongoing under-reporting of clinically re

✍ Schöffski, P; Garfield, D H; Hercbergs, A; Wolter, P 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 105 KB

A Phase II Safety and Efficacy Study of

✍ Pili, Roberto; Qin, Rui; Flynn, P.J.; Picus, Joel; Millward, Michael; Ho, Wing M 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 791 KB

Efficacy and safety of erlotinib HCl, an

✍ A.N. GORDON; N. FINKLER; R.P. EDWARDS; A.A. GARCIA; M. CROZIER; D.H. IRWIN; E. B 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB